1 day Ago By Defense World Staff
BrainsWay ( NASDAQ:BWAY – Get Free Report ) ‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They currently have a $16.00 price target on the stock.
HC Wainwright’s target price would indicate a potential upside of 93.24% from the stock’s previous close. Separately, Northland Securities lifted their target price on BrainsWay from $9.
00 to $11.00 and gave the stock an “outperform” rating in a report on Wednesday, August 7th. Read Our Latest Stock Analysis on BrainsWay BrainsWay Trading Down 1.
9 % BrainsWay ( NASDAQ:BWAY – Get Free Report ) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.04 earnings per share (EPS) for the quarter.
BrainsWay had a net margin of 1.67% and a return on equity of 1.45%.
The business had revenue of $10.01 million during the quarter, compared to analyst estimates of $9.40 million.
During the same quarter last year, the business earned ($0.05) EPS. On average, equities analysts forecast that BrainsWay will post 0.
06 EPS for the current year. Institutional Inflows and Outflows Institutional investors and hedge funds have recently modified their holdings of the stock. Tucker Asset Management LLC increased its holdings in BrainsWay by 1,686.
9% in the 4th quarter. Tucker Asset Management LLC now owns 5,450 shares of the company’s stock worth $35,000 after acquiring an additional 5,145 shares during the last quarter. Quadrature Capital Ltd bought a new position in BrainsWay during the fourth quarter worth about $70,000.
Virtu Financial LLC purchased a new position in shares of BrainsWay in the first quarter worth about $60,000. Rhumbline Advisers raised its position in shares of BrainsWay by 10.3% in the second quarter.
Rhumbline Advisers now owns 18,077 shares of the company’s stock valued at $110,000 after purchasing an additional 1,695 shares during the period. Finally, Perritt Capital Management Inc bought a new stake in shares of BrainsWay in the second quarter valued at approximately $121,000. 30.
11% of the stock is owned by institutional investors. About BrainsWay ( Get Free Report ) BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally.
It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. Featured Stories Five stocks we like better than BrainsWay What Are Dividends? Buy the Best Dividend Stocks Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion? What is a Bond Market Holiday? How to Invest and Trade Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge EV Stocks and How to Profit from Them Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker Receive News & Ratings for BrainsWay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BrainsWay and related companies with MarketBeat.com's FREE daily email newsletter .
.
